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SUMMARY
Aberrant TGFb signaling is common in human cancers and contributes to tumor metastasis. Here, we
demonstrate that Gr-1+CD11b+ myeloid cells are recruited into mammary carcinomas with type II TGFb
receptor gene (Tgfbr2) deletion and directly promote tumor metastasis. Gr-1+CD11b+ cells infiltrate into
the invasive front of tumor tissues and facilitate tumor cell invasion and metastasis through a process involv-
ing metalloproteinase activity. This infiltration of Gr-1+CD11b+ cells also results in increased abundance of
TGFb1 in tumorswith Tgfbr2 deletion. The recruitment of Gr-1+CD11b+ cells into tumorswith Tgfbr2 deletion
involves two chemokine receptor axes, the SDF-1/CXCR4 and CXCL5/CXCR2 axes. Together, these data
indicate that Gr-1+CD11b+ cells contribute to TGFb-mediated metastasis through enhancing tumor cell
invasion and metastasis.INTRODUCTION
Mounting evidence indicates that alterations in TGFb signaling
have significant effects on tumor initiation and progression (Bi-
erie and Moses, 2006). TGFb signals through the type I and
type II TGFb receptors (TbRI and TbRII, respectively), resulting
in phosphorylation of Smad2 and Smad3, which then combine
with Smad4 to enter the nucleus tomodulate transcription (Bierie
and Moses, 2006). In addition, TGFb binding to its receptors
activates many noncanonical signaling pathways. TGFb can
function as a tumor suppressor or a tumor promoter depending
on the context and stage of tumor progression. Mutations of the
genes encoding TbRI and TbRII (TGFBR1 and TGFBR2, respec-
tively) have been reported in a number of human cancers(Akhurst and Derynck, 2001). Mutations in TGFBR2 are particu-
larly frequent in tumors with microsatellite instability (Grady and
Markowitz, 2002). Although mutations in TGFb receptor genes
are infrequent in human breast cancers, there is compelling
evidence for impairment of TGFb signaling in this disease
(Bagadi et al., 2007; Chen et al., 1998, 2006; Seitz et al., 2003).
Decreased expression of TbRII occurs frequently both in early
and advanced breast cancer (de Jong et al., 1998; Gobbi
et al., 1999). Further, polymorphisms in TGFBR1 that result in
decreased TGFb signaling are associated with an increased
frequency and metastasis of breast cancer (Chen et al., 2006;
Pasche et al., 2005). Transgenic animal studies indicate that
a simple reduction of TGFb signaling is sufficient to predispose
to the development of mammary carcinomas (Tang et al., 1998).SIGNIFICANCE
TGFb is a very important tumor suppressor. Inactivation of TGFb signaling frequently occurs in human cancers and contri-
butes to tumor metastasis. However, the contribution of host cells in this process is unclear. Here, we show that deletion of
Tgfbr2 in mammary carcinoma cells results in increased chemokine signals that enhance Gr-1+CD11b+ myeloid cell infil-
tration into tumors, which leads to enhanced tumor invasion and metastasis. Gr-1+CD11b+ cell infiltration also results in
increased TGFb production in tumors with Tgfbr2 deletion. Thus, the tumor-suppressing role of TGFb can be switched
to tumor promoting through the recruitment of Gr-1+CD11b+ cells in the tumor microenvironment. Inhibition of
Gr-1+CD11b+ cell production/recruitment could improve host immunosurveillance and inhibit tumor metastasis, having
the effect of ‘‘killing two birds with one stone.’’Cancer Cell 13, 23–35, January 2008 ª2008 Elsevier Inc. 23
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TGFb Mediates Metastasis via Gr-1+CD11b+ CellsConditional knockout of Tgfbr2 in combination with expres-
sion of KrasG12D in pancreatic cancer (Ijichi et al., 2006) or with
APC mutation in intestinal carcinomas (Munoz et al., 2006) re-
sulted in the development of aggressive tumor phenotype. We
have shown that conditional deletion of Tgfbr2 in mammary ep-
ithelial cells that also express the polyoma middle T antigen
(PyVmT) under the MMTV promoter resulted in a shortened
tumor latency and an increased metastases (Forrester et al.,
2005; Ijichi et al., 2006; Munoz et al., 2006). However, others
have shown that enhancement of TGFb signaling by expression
of a constitutively active TGFb1 (Muraoka et al., 2003; Muraoka-
Cook et al., 2004) or TbRI (Muraoka-Cook et al., 2004, 2006;
Siegel et al., 2003) in mammary epithelial cells in conjunction
with c-Neu of PyVmT expression increases pulmonary metasta-
ses creating a conundrum. It is unclear what mechanisms under-
lie these different observations.
Host-derived inflammatory cells infiltrate into tumor tissues
and create an environment that favors tumor progression. They
promote tumor angiogenesis and tumor progression by produc-
ing angiogenic factors and matrix-degrading enzymes (Balkwill
and Coussens, 2004; Coussens and Werb, 2002). The recruit-
ment of inflammatory cells to tumor sites is regulated by the
interactions of chemokines and chemokine receptors. ENA-78/
CXCL5, interacting with CXCR2, is responsible for the recruit-
ment of polymorphonuclear neutrophils into inflamed lungs
(Ahuja and Murphy, 1996; Bozic et al., 1996; Jeyaseelan et al.,
2005; Zineh et al., 2006). In addition, stromal-derived factor 1
(SDF-1 or CXCL12) is considered one of the key regulators of
hematopoietic stem and progenitor cell trafficking between the
peripheral circulation and targeted tissues. SDF-1 mediates its
effects on chemotaxis through its receptor, CXCR4, which is
highly expressed on putative stem and progenitor cells (Balkwill
and Coussens, 2004).
Gr-1+CD11b+myeloid cells, also called myeloid immune sup-
pressor cells (MISCs) or myeloid-derived suppressor cells
(MDSCs), are significantly overproduced in the bone marrow
and spleens of tumor-bearing mice (Melani et al., 2003; Serafini
et al., 2006) as well as in peripheral blood of cancer patients
(Almand et al., 2001; Young and Lathers, 1999). In mice they
express CD11b, a marker for myeloid cells of the macrophage
lineage, and a marker for granulocytes, Gr-1, thus they are also
called Gr-1+CD11b+ cells. In human cancer patients, Gr-1+
CD11b+ myeloid cells are identified as lineage (CD3, CD14,
CD19, and CD57) and HLA-DR negative (LinHLA-DR), or im-
mature dendritic cells. Gr-1+CD11b+ myeloid cells have been
demonstrated to be immune suppressive since the 1980s
(Almand et al., 2001; Bronte et al., 2000; Gabrilovich et al.,
1996; Serafini et al., 2004, 2006; Young and Lathers, 1999).
They represent one mechanism of tumor escape from immune
system control and compromise the efficacy of cancer immuno-
therapy.
Recently, Gr-1+CD11b+ cells were found to infiltrate into tu-
mors and promote tumor angiogenesis by producing high levels
of MMP9 and by directly incorporating into tumor endothelium
(Yang et al., 2004). Gr-1+CD11b+ cells have also been impli-
cated in tumor refractoriness to anti-VEGF treatment (Shojaei
et al., 2007). Despite the data defining the overproduction in
tumor hosts and infiltration in tumor tissues, themolecular mech-
anisms for their recruitment and roles in tumor progression24 Cancer Cell 13, 23–35, January 2008 ª2008 Elsevier Inc.remain to be investigated. Here we show that Gr-1+CD11b+
cells are specifically recruited into mammary carcinomas with
conditional deletion of Tgfbr2 and 4T1 tumors through two
distinct chemokine mechanisms, CXCL5/CXCR2 and SDF-1/
CXCR4. These immature myeloid cells directly promote tumor
invasion andmetastasis through increased production and func-
tion of MMPs. In addition, Gr-1+CD11b+ cell infiltration also re-
sults in an increased TGFb production in the microenvironment
of tumors with Tgfbr2 deletion. These findings improve our un-
derstanding of tumor-host interaction. Therapeutic interventions
on Gr-1+CD11b+ cells may not only enhance the host immune
system but also inhibit tumor invasion and metastasis.
RESULTS
Gr-1+CD11b+ Cells Are Recruited to Mammary
Carcinomas with Genetic Deletion of Tgfbr2,
Especially in the Invasive Front
We have previously reported that conditional deletion of Tgfbr2
in mammary epithelial cells also expressing PyVmT results in
a shortened tumor latency and an increased pulmonarymetasta-
sis compared to PyVmT carcinomas with intact TGFb signaling
(Chytil et al., 2002; Forrester et al., 2005). We have also reported
that Gr-1+CD11b+ myeloid cells infiltrate into tumor tissues and
contribute to tumor angiogenesis (Yang et al., 2004). To examine
the role of Gr-1+CD11b+ cells in TGFb-mediated tumor progres-
sion, tumor tissues were collected 1 week after palpable tumors
developed in a PyVmT genetic tumor model with Tgfbr2 knock-
out (Tgfbr2MGKO). Single-cell suspension from tumor tissues of
Tgfbr2MGKO and floxed PyVmT control mice (Tgfbr2flox/flox)
were analyzed by flow cytometry. We observed a significant
increase of Gr-1+CD11b+ cells in the PyVmT/Tgfbr2MGKO com-
pared with their Tgfbr2flox/flox control tumors (Figures 1A and 1B).
Gr-1+CD11b+ cells residing in tumor tissues express both Gr-1
and CD11b, and no distinct Gr-1 alone population was found
(Figure 1C). This allowed us to examine the precise location of
Gr-1+CD11b+ cells in tumor tissues with immunohistochemistry
staining with anti-Gr-1 antibody. Very interestingly, Gr-1+CD11b+
cells were foundmostly in the invasive front of PyVmT/Tgfbr2MGKO
mammary tumors (Figure 1D). In addition to Gr-1+CD11b+ cells,
we also observed an increased infiltration of F4/80-positive and
VEGFR1-positive cells in the PyVmT/Tgfbr2MGKO tumors com-
pared with their Tgfbr2flox/flox control tumors (Figures 1E and 1F),
although without statistical significance. We thus concentrated
our studies on Gr-1+CD11b+ myeloid cells. The significant in-
crease of Gr-1+CD11b+ cells is consistent with increased lung
metastasis in those animals (Forrester et al., 2005), suggesting
that these Gr-1+CD11b+ cells may play a role in breast tumor
metastasis.
Gr-1+CD11b+ Cells Promote Mammary
Carcinoma Metastasis
To confirm our observation in PyVmT/Tgfbr2MGKO tumors, we
utilized a 4T1 orthotopic tumor model. This tumor model shares
many characteristics with human breast cancer, particularly its
ability to spontaneously metastasize to lungs. In addition, 4T1
tumors showed significantly decreased growth inhibition by
TGFb relative to normal mammary epithelial cells or PyVmT/
Tgfbr2flox.flox carcinoma cells (data not shown). Importantly,
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TGFb Mediates Metastasis via Gr-1+CD11b+ CellsGr-1+CD11b+ cells were significantly overproduced in bone
marrow and spleens of mice bearing large 4T1 tumors (Fig-
ure 2A). The number of Gr-1+CD11b+ cells increased with the
growth of the tumor, with over 50% in the spleen, and over
80% in the bone marrow 28–35 days after tumor inoculation.
This allows us to be able to sort large number of Gr-1+CD11b+
cells to investigate their roles in breast tumor metastasis using
both in vivo and in vitro assays. In 4T1 breast tumors, Gr-1+
CD11b+ cells comprised an average of 7.2% of total cells
(Figure 2B). Gr-1+CD11b+ cells were mostly present in the inva-
sive front (Figure 2C),which is similar to theMMTVPyVmTmodel.
To examine the role of Gr-1+CD11b+ cells in tumor metasta-
sis, 4T1 cells were injected into the mammary fat pad of female
Balb/c mice, with or without Gr-1+CD11b+ cells sorted from 4T1
tumor tissues or spleens of mice bearing 4T1 tumors. Gr-1+
CD11b+ cells from normal spleens were used as a control. We
achieved a 95%–98% purity of sorted Gr-1+CD11b+ cells
(Figure 2D). Theprimary tumorswere removedafter 12 to 14days,
which allows metastasis to develop in lungs avoiding morbidity
or mortality caused by large primary tumors. Lungs were har-
Figure 1. Gr-1+CD11b+ Myeloid Cells Are
Recruited to Mammary Carcinomas with
Genetic Deletion of Tgfbr2
(A) Flow cytometry analysis of infiltrating Gr-1+
CD11b+ cells in PyVmT/Tgfbr2MGKO tumors and
PyVmT/Tgfbr2flox/flox control tumors. Shown are
representative flow cytometry plots.
(B) Quantitative data for the presence of Gr-1+
CD11b+ cells in tumors as shown in (A). Five- to
seven-week-old mice were analyzed.
(C) Flow cytometry analysis of tumor-residing
Gr-1+CD11b+ cells in PyVmT/Tgfbr2MGKO tumors.
(D) IHC of Gr-1+CD11b+ cells in the invasive front
of PyVmT/Tgfbr2MGKO mammary carcinomas
compared with PyVmT/Tgfbr2flox/flox tumors.
Scale bars are indicated in the panels.
(E and F) Flow cytometry analysis of infiltrating
F4/80- and VEGFR1-positive cells in PyVmT/
Tgfbr2MGKO tumors and PyVmT/Tgfbr2flox/flox con-
trol tumors. Representative flow cytometry plots
are shown on the left and quantitative data on
the right. m.g., adjacent mammary gland tissue;
tu, tumor tissues. All quantitative data are pre-
sented as the mean ± standard error.
vested and the tumor nodules were
counted after the mice showed evi-
dence of distress. We observed a signif-
icant increase of tumor nodules in lungs
from mice that received 4T1 coinjection
with Gr-1+CD11b+ cells derived from
tumor tissues or spleens of tumor-bear-
ing animals compared with 4T1 alone or
4T1 with normal Gr-1+CD11b+ cells
(Figure 2E). These data confirm that
Gr-1+CD11b+ cells derived from tumor
hosts enhance tumor metastasis.
In further characterization of Gr-1+
CD11b+ cells, we found that, within the
Gr-1+CD11b+ cell population, there were
approximately 14% CD34+, 31% VEGFR1+, and 44% F4/80+
cells (see Figure S1 available online). These data support our
hypothesis that Gr-1+CD11b+ cells are constituted of immature
myeloid cells at different stages of differentiation.
Gr-1+CD11b+ Myeloid Cells Promote Mammary
Carcinoma Cell Invasion In Vivo and In Vitro
Very interestingly, after surgical removal of primary tumors, at the
primary injection site the recurrent tumors from 4T1 cells coin-
jected with tumor-derived Gr-1+CD11b+ cells were significantly
larger than those from control groups (Figure 3A). In addition, we
found no difference in primary tumor growth during the first
10–14 days after injection (data not shown). This indicates that
Gr-1+CD11b+ cells derived from tumor tissues or tumor spleens
increase tumor cell invasion to surrounding tissues, supporting
our earlier observation that Gr-1+CD11b+ cells promote
tumor metastasis, as invasion is the first step in the metastatic
process.
To further investigate the effects of Gr-1+CD11b+ cells on
tumor invasion, we performed in vitro invasion assays. 4T1 cellsCancer Cell 13, 23–35, January 2008 ª2008 Elsevier Inc. 25
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TGFb Mediates Metastasis via Gr-1+CD11b+ CellsFigure 2. Gr-1+CD11b+ Cells Promote Tumor Metastasis
(A) Increased Gr-1+CD11b+ cells in spleens and bone marrow of 4T1 tumor-bearing mice after tumor inoculation. (Left panel) Flow cytometry analysis of
Gr-1+CD11b+ cells in the spleen of tumor-bearing mice 28 days following engraftment (four or more mice per time point). (Middle panel) Spleen. (Right panel)
Bone marrow (b.m.).
(B) Gr-1+CD11b+ cells in 4T1 tumors with flow cytometry analysis.
(C) IHC showing Gr-1+CD11b+ cells in the invasive front of 4T1 tumors 15 days after tumor inoculation. Scale bar, 100 mM.
(D) Single-cell sorting of Gr-1+CD11b+ cells from tumors and spleens of 4T1 tumor-bearing mice 35 days after tumor inoculation. Flow cytometry analysis of
Gr-1+CD11b+ cells after sorting is shown.
(E) Metastasis was significantly increased when 4T1 cells were coinjected with tumor-derived Gr-1+CD11b+ cells including Gr-1+CD11b+ cells derived from
tumor tissues (tu inf Gr-1+CD11b+ cells) and spleens of tumor-bearing mice (tu sp Gr-1+CD11b+ cells). 4T1 cells alone and Gr-1+CD11b+ cells from normal
mice (nor Gr-1+CD11b+ cells) were used as controls. Number of animals used is indicated in the bar. m.g., adjacent mammary gland tissue; tu, tumor tissues.
Results are presented as the mean ± SE.were labeled with a green cell-tracking dye. Sorted Gr-1+
CD11b+ cells were labeled with a red cell-tracking dye. 4T1 cells
with or without Gr-1+CD11b+ cells were seeded into the top
chamber of transwell filters coated with Matrigel. 4T1 cells that
had invaded through the membrane were counted (eight to
ten fields per filter) after overnight incubation. We found that
4T1 cells mixed with Gr-1+CD11b+ cells displayed a signi-
ficant increase in tumor cell invasion (Figures 3B and 3C). Inter-
estingly, GM6001 (1 mM), a broad-spectrum MMP inhibitor,
completely attenuated the observed invasion (Figure 3C). These
results are in agreement with our in vivo findings that
Gr-1+CD11b+ cells directly promote tumor cell invasion and
metastasis.26 Cancer Cell 13, 23–35, January 2008 ª2008 Elsevier Inc.Further, we observed significantly more invasive areas in the
PyVmT/Tgfbr2MGKO tumors than in the PyVmT/Tgfbr2flox.flox
tumors when the two tumor types were at the same stage and
were similar in size (Figures S2A and S2C). The invasive areas
in the PyVmT/Tgfbr2MGKO tumors are often filled with a large
number of Gr-1+CD11b+ cells (Figure S2B). Immunofluores-
cence staining of E-Cadherin did not show significant changes
in E-Cadherin expression between the PyVmT/Tgfbr2MGKO and
control tumors, indicating that EMT is unlikely to be involved in
PyVmT/Tgfbr2MGKO tumor invasion (Figures S2D and S2E).
These data suggest that PyVmT/Tgfbr2MGKO tumor invasion
may be aided by Gr-1+CD11b+ cells through a collective event
between Gr-1+CD11b+ cells and tumor cells.
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TGFb Mediates Metastasis via Gr-1+CD11b+ CellsTumor-Residing Gr-1+CD11b+ Cells Exhibit Elevated
Production and Function of MMPs
MMPs contribute to tumor progression and metastasis (Lynch
and Matrisian, 2002). Microarray analyses indicated that
MMP14 (MT1-MMP), MMP13, and MMP2 are highly elevated in
tumor-residing Gr-1+CD11b+ cells when compared with those
from spleens (data not shown). We further confirmed the results
with real-time RT-PCR (Figures 4A and 4B). Since inhibition of
MMP activity abolishes Gr-1CD11b+ cell-mediated tumor inva-
sion in vitro (Figure 3C), we performed in situ zymography using
a quenched fluorogenic substrate that releases fluorescent
peptides upon cleavage by gelatinases. This assay allows us to
examine the functionality ofMMPs in Gr-1+CD11b+ cells directly
in tumor tissues. As expected, very strong fluorescence intensity
was localized in the tumor-mammary tissue interface where we
had observed significant number of Gr-1+CD11b+ cells (Figures
4Ca–4Cc for 4T1 tumors and Figures 4Cd for MMTV-PyVmT/
Tgfbr2MGKO tumors). This was not observed in controls treated
with EDTA (Figure 4Ce). Taken together with the in vitro data
Figure 3. Gr-1+CD11b+ Myeloid Cells
Increased 4T1 Tumor Invasion In Vivo and
In Vitro
(A) Increased growth of recurrent tumors with 4T1
cells coinjected with Gr-1+CD11b+ cells derived
from tumor tissues, or spleens of tumor-bearing
mice. Number of animals is indicated in the bar.
Results are presented as the mean ± SE.
(B) Fluorescent microscopy of 4T1 cells that in-
vaded through a Matrigel-coated transwell when
coculturedwith tumor-derivedGr-1+CD11b+ cells
(Bb) compared to normal Gr-1+CD11b+ cells (Ba).
4T1 cells were labeled with a green tracking dye,
and Gr-1+CD11b+ cells were labeled with a red
tracking dye. (Bc) Close interaction between 4T1
cells and Gr-1+CD11b+ cells.
(C) An MMP inhibitor (GM6001, 1 mM) blocked
Gr-1+CD11b+ cell-promoted 4T1 cell invasion in
vitro. Results are from two experiments with tripli-
cates for each group and are presented as the
mean ± SE. m.g., adjacent mammary gland tissue;
tu, tumor tissues; tu inf Gr-1+CD11b+ cells, Gr-1+
CD11b+ cells from tumor tissues; tu sp Gr-1+
CD11b+ cells, Gr-1+CD11b+ cells from spleens
of tumor-bearing mice; nor Gr-1+CD11b+ cells,
Gr-1+CD11b+ cells from spleens of normal mice.
Scale bar, 50 mM for all panels.
demonstrating a requirement for metallo-
proteinase activity, we suggest that tu-
mor-residing Gr-1+CD11b+ cells pro-
duce multiple MMPs that contribute to
breast tumor cell invasion.
Increased TGFb Production in
Mammary Carcinomas with
Genetic Deletion of Tgfbr2
In characterizing mammary carcinomas
with Tgfbr2 deletion, we found that they
contained significantly higher levels of
TGFb1 than the control tumor without
Tgfbr2 deletion (Figure 5A). Because significantly more Gr-1+
CD11b+ cells infiltrate into tumors with Tgfbr2 deletion, and
our preliminary data from microarray analysis indicated that
Gr-1+CD11b+ cells produce large amount of TGFb1, we rea-
soned that Gr-1+CD11b+ cells may contribute to increased
TGFb1 production in these tumors. We measured TGFb1 in
Gr-1+CD11b+ cells by ELISA. Gr-1+CD11b+ cells derived from
tumor spleens produced significantly higher levels of TGFb1
than those from normal spleens (Figure 5B, left panel). No dif-
ference was found in TGFb1 production between tumor cell
lines derived from mammary adenocarcinoma with or without
Tgfbr2 deletion (Figure 5B, right panel). Immunohistochemistry
of tumor sections further demonstrates that TGFb1-positive cells
are mostly stromal cells (Figure 5C), especially in the invasive
front where Gr-1+CD11b+ cells were mostly present (Fig-
ure 5C). These data support our observation that Gr-1+
CD11b+ cells are likely one of the sources for increased TGFb1
production in mammary carcinomas with genetic deletion of
Tgfbr2.Cancer Cell 13, 23–35, January 2008 ª2008 Elsevier Inc. 27
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TGFb Mediates Metastasis via Gr-1+CD11b+ CellsMechanisms of Gr-1+CD11b+ Cell Recruitment
to Tumors
Our microarray analyses indicate that CXCL5 was significantly
increased in PyVmT/Tgfbr2MGKO tumors compared with the
PyVmT/Tgfbr2flox/flox tumors (data not shown). We further con-
firmed this observation with ELISA assays using cell culture
supernatant from established cell lines (Figure 6A, left panel).
Interestingly, we also observed elevated CXCL5 production in
carcinoma cells with coexpression of a dominant-negative type
II TGFb receptor (DNIIR) with c-Neu under the MMTV promoter
compared to c-Neu carcinoma cells (Figure S3A). In addition,
pancreatic cancers with Tgfbr2 deletion also showed increased
CXCL5production (H. Ijichi andH.L.M., unpublisheddata). These
data indicate that CXCL5 may be a common mechanism in the
tumormicroenvironment with deleted or decreased TGFb signal-
ing. Further analysis confirmed that recombinant CXCL5
increased Gr-1+CD11b+ cell migration in vitro (Figure 6B), and
neutralizing CXCL5 using a monoclonal antibody significantly
blocked the migration of Gr-1+CD11b+ cells in response to
PyVmT/Tgfbr2MGKO cell-conditioned medium (Figure 6B). To ex-
amine the role of theCXCL5/CXCR2 inGr-1+CD11b+ cell recruit-
ment to the tumor microenvironment in vivo, we transplanted
breast adenocarcinoma with or without Tgfbr2 deletion into the
number fourmammary gland in syngeneic FVBmice and allowed
tumors to grow for 14 days. We then treated mice with equal
tumor sizes with a specific CXCR2 antagonist, SB-265610, at
2 mg/kg/day for 2 weeks through i.p. injection. SB-265610 has
been shown to have selective inhibition on neutrophil accu-
mulation when used at 1–3 mg/kg/day (Auten et al., 2001). We
found that the SB-265610 treatment significantly inhibited the
Figure 4. Increased Production and
Function of MMPs in Tumor-Residing
Gr-1+CD11b+ Cells
(A and B) Real-timeRT-PCR ofMMP14 andMMP2
(A) as well as MMP13 (B) in Gr-1+CD11b+ cells
derived from tumor tissues compared with those
from spleens. Results are presented as the
mean ± SE.
(C) In situ zymography of MMPs in 4T1 mammary
carcinomas and PyVmT/Tgfbr2MGKO carcinomas.
Abundant green fluorescence (indicator of MMP
activities) was observed in the invasive front of
4T1 tumors (Ca and Cc) and PyVmT/Tgfbr2MGKO
carcinomas (Cd). Nuclei were labeled with 7AAD
(red). Tumor sections treated with EDTA were
used as negative controls (Ce). Scale bar, 50 mM
for all panels. m.g., adjacent mammary gland
tissue; tu, tumor tissues.
recruitment of Gr-1+CD11b+ cells to the
mammary adenocarcinoma with Tgfbr2
deletion but not the control tumors (Fig-
ure 6C),with no significant effect on tumor
growth (data not shown). Gr-1+CD11b+
cells isolated from PyVmT/Tgfbr2MGKO
tumor tissues express CXCR2, in levels
that are modestly elevated compared to
splenic Gr-1+CD11b+ cells (data not
shown). These data indicate that elevated
CXCL5 production but not the corresponding CXCR2 receptor
regulates the recruitment of Gr-1+CD11b+ cells in the PyVmT/
Tgfbr2MGKO tumor microenvironment.
The SDF-1/CXCR4 chemokine axis mediates recruitment of
several cell types, including hematopoietic progenitor cells
(Burger and Kipps, 2006; Mohle et al., 1998; Peled et al., 1999;
Urbich andDimmeler, 2004). Thus, we examinedCXCR4 expres-
sion in Gr-1+CD11b+ cells using flow cytometry analysis. Tumor
infiltrating Gr-1+CD11b+ cells express significantly increased
CXCR4 when compared with those derived from spleens of
tumor-bearing mice (Figure 6D). This includes Gr-1+CD11b+
cells from 4T1 and PyVmT/Tgfbr2MGKO tumors (Figure 6D), sug-
gesting that upregulated CXCR4 expression is an intrinsic
property of these cells regardless of differences in the tumor
microenvironment to which they are recruited. Gr-1+CD11b+
cells isolated from tumor tissues migrated in response to re-
combinant SDF-1 in vitro (Figure 6E). Importantly, neutralizing
CXCR4 using an antibody significantly blocked this process
(Figure 6E). In addition to CXCR4, CXCR7 has been identified
as another signaling receptor for SDF-1 (Balabanian et al.,
2005; Burns et al., 2006). We found that approximately 19% of
Gr-1+CD11b+ cells are CXCR7 positive (Figure S3B). Thus,
Gr-1+CD11b+ cells could also be recruited through the SDF-1/
CXCR7. Together, our data suggest that tumor-residing
Gr-1+CD11b+ cells are recruited to tumor tissues through
SDF-1/CXCR4 and potentially through CXCR7 interaction. In
addition, PyVmT/Tgfbr2MGKO tumors have increased production
of CXCL5 that is also responsible for the recruitment of
Gr-1+CD11b+ cells to tumors with deleted or decreased TGFb
signaling.28 Cancer Cell 13, 23–35, January 2008 ª2008 Elsevier Inc.
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TGFb Mediates Metastasis via Gr-1+CD11b+ CellsTo further examine the critical roles of Gr-1+CD11b+ cell re-
cruitment in PyVmT/Tgfbr2MGKO tumor invasion and metasta-
ses, we transplanted breast adenocarcinoma with Tgfbr2 dele-
tion into the number four mammary gland in syngeneic FVB
mice and allowed tumors to establish for 7 days.We then treated
the mice with a CXCR2-specific antagonist, SB-265610, at
2 mg/kg/day, through i.p. injection or a CXCR4 antagonist,
AMD3100, at 1.25 mg/kg/day twice daily through s.c injection,
or both for 10 days. The primary tumors were then surgically
removed. The mice were allowed to live for another 3 weeks
for tumor metastasis development in the lungs. The effects of
the antagonist on tumor metastasis, tumor growth, and invasion
were evaluated. We found that lung metastasis is significantly in-
hibited when mice are treated with the CXCR2 antagonist, the
CXCR4 antagonist, or CXCR2 and CXCR4 antagonists when
compared with vehicle controls (Figure 6F). No significant differ-
ence in primary tumor growth was found between the treatment
and the controls (data not shown). H&E staining of the tumor
tissues showed that the degree of tumor invasion in mice treated
with CXCR2, CXCR4, or both was reduced when compared with
the vehicle controls (Figures S2F–S2J). These data, together
with data from in vitro coculture (Figures 3B and 3C) and the
effect of in vivo coinjection of tumor cells with Gr-1+CD11b+
cells (Figures 3A and 2E) strongly suggest that Gr-1+CD11b+
cells are critical players in tumor cell invasion and metastasis
formation.
Figure 5. Increased TGFb1 Production in
Mammary Carcinomas with Genetic Dele-
tion of Tgfbr2
(A) Increased TGFb1 production in PyVmT/
Tgfbr2MGKO tumors compared with PyVmT/
Tgfbr2flox/flox tumors. n = 4 mice per group.
(B) (Left panel) Gr-1+CD11b+ cells from spleens of
mice bearing large 4T1 tumors exhibited signifi-
cantly higher TGFb1 production when compared
with Gr-1+CD11b+ cells from normal spleens.
n = 2 mice per group. (Right panel) No difference
of TGFb1 production was found between tumor
cell lines derived from PyVmT/Tgfbr2MGKO tumors
versus PyVmT/Tgfbr2flox/flox tumors. TGFb1 in
conditioned media was measured by ELISA.
Results are presented as the mean ± SE.
(C) Gr-1+CD11b+ cells are likely the resource for
increased TGFb1 production in mammary carci-
nomas with genetic deletion of Tgfbr2. IHC of
TGFb1 (left panel) shows that TGFb1-positive cells
are mostly in the invasive front where Gr-1+
CD11b+ cells were mostly present (right panel
with Gr-1 staining). Scale bar, 50 mM for both
panels. m.g., adjacent mammary gland tissue; tu,
tumor tissues.
Immature Myeloid Cells in Human
Breast Tumors
Finally, we investigated human breast
carcinomas for the presence of immature
myeloid cells. We chose myeloperoxi-
dase (MPO) as amarker for human imma-
ture myeloid cells for IHC. This is based
on the following: (1) expression of MPO
is significantly elevated in Gr-1+CD11b+ immature myeloid cells
from several mouse models by microarray analysis (data not
shown); (2) MPO, a hemoprotein, is abundantly expressed in
neutrophils. MPO possesses proinflammatory properties and
participates in tumor initiation and progression (Knaapen et al.,
2006). We examined eight cases of human breast carcinoma tis-
sues. MPO-positive cells were clearly abundant in the invasive
front of all samples examined (Figure 7A). These include the front
in thecollagen-rich area (Figures 7Aa–7Ac) and the front innormal
mammary fat tissues (Figures 7Ad–7Af). MPO-positive cells were
found in both situations (Figures 7Aa and 7Ad). H&E staining of
these tumor tissues further supports our observations (Figures
7Ab and 7Ae). To further confirm the infiltrating myeloid cells in
human breast tumor tissues, we utilized flow cytometry technol-
ogy.We labeled single-cell suspensions from fresh humanbreast
ductal adenocarcinomas (stages 2–3) with antibody cocktails.
These include antibodies for lineage identification: CD3 for
T cell; CD19 for B cell; CD56 for NK cell; CD40/CD86/HLA-DR
for dendritic cells; and CD14 for monocytes; and antibodies for
myeloid cell marker, including CD33, CD34, and CD15. The my-
eloid markers are typically used for examining the peripheral
blood of patients with myelodysplasia. Tumor-infiltrating imma-
ture myeloid cells were identified as T, B, NK, monocyte, and
dendritic cell lineage negative and positive for CD33, CD34,
and CD15 myeloid markers. The percentage of immature mye-
loid cells was evaluated for each patient, with four patients total.Cancer Cell 13, 23–35, January 2008 ª2008 Elsevier Inc. 29
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TGFb Mediates Metastasis via Gr-1+CD11b+ CellsFigure 6. Mechanisms of Recruitment of Gr-1+CD11b+ Cells to the Tumor Microenvironment
(A) Elevated production of CXCL5 in cell culture supernatant of PyVmT/Tgfbr2MGKO mammary carcinomas.
(B) In vitro migration of Gr-1+CD11b+ cells in response to CXCL5. Gr-1+CD11b+ cells that migrated after 6–8 hr incubation were counted and plotted. Shown is
one of the representative experiments of three performed.
(C) Inhibition of Gr-1+CD11b+ cell recruitment to PyVmT/Tgfbr2MGKO tumors with CXCR2 antagonism. Percentage of Gr-1+CD11b+ cells in all cells from
PyVmT/Tgfbr2MGKO and control tumors were plotted. Mice bearing PyVmT/Tgfbr2MGKO and control tumors were treated with a CXCR2-specific antagonist,
SB-265610, at 2 mg/kg/day for 2 weeks through i.p. injection.
(D) Flow cytometry analysis of CXCR4 expression in infiltrating Gr-1+CD11b+ cells from 4T1 tumors as well as PyVmT/Tgfbr2MGKO tumors, compared with those
from spleens of the same tumor-bearing mice (as labeled). Histogram of CXCR4 expression was gated on Gr-1+CD11b+ double-positive cells. Shown is one of
the representative mice analyzed; n = 3–5 mice per group.30 Cancer Cell 13, 23–35, January 2008 ª2008 Elsevier Inc.
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tumor tissues are these myeloid cells (Figure 7B). Together, our
data suggest that immature myeloid cells participate not only in
tumor invasion in mouse models but also likely in human breast
cancers. Collectively, our findings point out a strategy to target
tumor metastasis by disrupting immature cell recruitment to
tumors.
DISCUSSION
Using the MMTV PyVmT mouse model we demonstrate that de-
letion of Tgfbr2 in mammary carcinomas specifically enhances
recruitment of Gr-1+CD11b+ myeloid cells to the invasive front.
We further demonstrate that Gr-1+CD11b+ cells promote tumor
invasion and metastasis through increased MMP production.
TGFb functions as a tumor suppressor or a tumor promoter
depending on the context and stage of tumor progression. We
and others have shown that abrogation of TGFb signaling with
deletion of Tgfbr2 resulted in aggressive tumor progression in
several mouse models (Biswas et al., 2004; Forrester et al.,
2005; Ijichi et al., 2006; Munoz et al., 2006; Lu et al., 2006). How-
ever, other reports show that the enhancement of TGFb signaling
in mammary epithelial cells in conjunction with c-Neu or PyVmT
increases pulmonary metastases (Muraoka et al., 2003; Mur-
aoka-Cook et al., 2004, 2006). These seem to be contradicting
observations, which now could be explained by the recruitment
of Gr-1+CD11b+ cells into the tumor microenvironment. Our
data suggest that autologous TGFb signaling in mammary
epithelial cells act as a tumor suppressor; when it is deleted or
altered, it results in Gr-1+CD11b+ cell recruitment. This leads
to increasedMMP and TGFb production that enhances tumor in-
vasion and metastasis. The switch of TGFb signaling from tumor
suppressor to tumor promoter thus involves an additional com-
ponent, which is the recruitment of Gr-1+CD11b+ cells in the tu-
mor microenvironment. Indeed, inflammatory cells (CD45- and
BM8-positive cells) have been observed in head-and-neck tu-
mors lacking TGFb signaling (Lu et al., 2006). In addition, inflam-
mation causes precancerous lesions in mice with TGFb1 defi-
ciency that can progress to colon cancer (Engle et al., 2002).
Very recently, CCR1+ myeloid cells (CD34+) have been shown
to be recruited to colon cancers with deletion of Smad4 and to
promote tumor invasion (Kitamura et al., 2007). These CCR1+
cells seem to be different fromGr-1+CD11b+ cells we described
here, as they do not express high levels of Gr-1.
Several lines of evidence make the contribution of Gr-
1+CD11b+ to tumor metastasis particularly interesting. (1) These
cells are overproduced in tumor hosts that include cancer
patients with a variety of tumors. (2) Gr-1+CD11b+ cells are com-
posed of immature myeloid cells at the early stages of differenti-
ation (Almand et al., 2001; Yang et al., 2004). They are different
from terminally differentiated tumor-associated macrophages
(TAM), identified as Mac-1 (CD11b) and F4/80+, which have
been shown to promote tumor progression and metastasis
through elevated CSF-1 production and enhanced EGF signalingin cancer cells (Condeelis and Pollard, 2006). Similarities be-
tween TAM and these immature myeloid cells were noticed
from profiling work (Biswas et al., 2006); however, differences
between the two populations were also evident. For example,
myeloid suppressor cells produce high levels of TGF-b1,
Figure 7. Immature Myeloid Cells in Human Breast Tumor Tissues
(A) IHC staining of myeloperoxidase to identify bonemarrow-derived immature
myeloid cells at the invasive front of human breast ductal adenocarcinomas
(Aa and Ad). (Ab) is anH&E-stained section serial to (Aa); (Ae) is anH&E-stained
section serial to (Ad). (Ac) and (Af) are negative controls. Scale bar, 100 mM for
all panels.
(B) Flow cytometry analysis of immature myeloid cells from single-cell suspen-
sion of human breast ductal adenocarcinomas (stages 2–3). The analyzed cells
were gated as 7AAD negative (top left panel, P1); negative for lineage markers
including CD3 for T cell, CD19 for B cell, CD56 for NK cell, CD40/CD86/HLA-
DR for dendritic cells, and CD14 for monocytes; and CD33, CD34, and CD15
positive (top right panel, P2). A histogram for FITC-positive myeloid cells is
shown in the lower right pane, with isotype control in the lower left panel.(E) In vitro migration of Gr-1+CD11b+ cells in response to SDF-1. Gr-1+CD11b+ cells that migrated after 6–8 hr incubation were counted and plotted. Shown is
one representative experiment of three performed.
(F) PyVmT/Tgfbr2MGKO tumor metastasis with blockade of CXCR2, CXCR4, or both. Tumor nodules in lung were counted after mice bearing 14 day tumors were
treated with CXCR2 or CXCR4 antagonists or both for 3 weeks. All results are presented as the mean ± SE.Cancer Cell 13, 23–35, January 2008 ª2008 Elsevier Inc. 31
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lated TAMs and was not further increased by M2-biasing cyto-
kines (Biswas et al., 2006). Gr-1+CD11b+ cells are also different
from two other cell types in the tumor microenvironment, neutro-
phils and mast cells, which express Gr-1 but not CD11b. (3) Gr-
1+CD11b+ cells interact with other host immune cells including
T, B, and NK cells. These immune cells may dictate the tumor
microenvironment through a shift from inflammation/immune re-
sponse to anti-inflammatory/immune-suppressive responses
(Th1/Th2-like cytokine shift) and may be responsible in the
metastatic liver milieu (Budhu et al., 2006). It is unclear whether
systemic immune suppression and direct participation in tumor
progression are two different properties or different manifesta-
tions of the same process.
Our data demonstrate that at least two distinct chemokine
axes regulate the recruitment of Gr-1+CD11b+ cells in tumor
tissues. One is SDF-1/CXCR4. Interestingly, tumor-residing
Gr-1+CD11b+ cells, from bothmammary tumors with Tgfbr2 de-
letion and 4T1 tumors, express high levels of CXCR4 when com-
pared with controls (Figure 6D). This indicates that upregulation
of CXCR4 in Gr-1+CD11b+ cells is an intrinsic property of Gr-1+
CD11b+ cells regardless of the difference in the tumor micro-
environments into which they are recruited. SDF-1/CXCR4 has
been implicated in the recruitment of hematopoietic stem and
progenitor cells (Balkwill and Coussens, 2004; Jin et al., 2006;
Mohle et al., 1998; Peled et al., 1999; Urbich and Dimmeler,
2004), supporting our observation that Gr-1+CD11b+ cells are
hematopoietic progenitors. In addition to the SDF-1/CXCR4
chemokine axis, mammary carcinomas with Tgfbr2 deletion
showed an increased production of CXCL5 (Figure 6A). The
role of CXCL5 in cancer-associated inflammation is indicated
in the prostate (Hochreiter et al., 2000). CXCL5 also has profound
angiogenic potential (Wente et al., 2006). Interestingly, elevated
CXCL5 production was also observed in dominant-negative
type II TGFb receptor/MMTV-C-Neu cells (Figure S3), indicating
CXCL5may be a result of diminished TGFb signaling in the tumor
microenvironment. These data suggested two distinct mecha-
nisms for Gr-1+CD11b+ cell recruitment: increased expression
of CXCR4 in Gr-1+CD11b+ cells as an intrinsic property and
elevated CXCL5 level in PyVmT/Tgfbr2MGKO tumors as tumormi-
croenvironment cues. When PyVmT/Tgfbr2MGKO tumors were
treated with a CXCR2-specific antagonist or a CXCR4 antago-
nist, there was a significantly decreased tumor metastasis,
strongly suggesting a critical role of Gr-1+CD11b+ cells in
PyVmT/Tgfbr2MGKO tumor invasion and metastases.
Gr-1+CD11b+ cells promote tumor metastasis, likely through
enhanced production and function of MMPs including MT1-
MMP (MMP14), MMP13, and MMP2. Treatment with a pan-
MMP inhibitor significantly attenuated tumor invasion in vitro.
MT1-MMP plays a crucial role in degrading extracellular matrix
and allows tumor cells to escape the matrix-enforced growth
control effect (Hotary et al., 2003). MT1-MMP is known to be
able to activate MMP2 and MMP13, both of which are associ-
ated with tumor invasion (d’Ortho et al., 1997; English et al.,
2001; Leeman et al., 2002; Nelson et al., 2000). Results from
our in vitro coculture (Figures 3B and 3C) and in vivo coinjection
of tumor cells with Gr-1+CD11b+ cells (Figures 3A and 2E)
strongly suggest a role for these cells in tumor invasion and
metastasis. In addition, PyVmT/Tgfbr2MGKO tumors, with a large32 Cancer Cell 13, 23–35, January 2008 ª2008 Elsevier Inc.number of Gr-1+CD11b+ cells, showed significantly more inva-
sive area compared with PyVmT/Tgfbr2flox.flox tumors. Further,
tumors treated with CXCR2 or CXCR4 antagonists showed
reduced invasiveness. These data suggest that the increased
invasion of PyVmT/Tgfbr2MGKO tumor may be aided by Gr-1+
CD11b+ cells through a collective event between Gr-1+CD11b+
cells and tumor cells, with the myeloid cells providing MMPs.
We cannot rule out the contribution of other factors produced
by Gr-1+CD11b+ cells to tumor cell invasion, but our results
strongly suggest that an induction of proteolytic activity is a
major contributing factor. In addition, the observed increased tu-
mor growth and metastasis-promoting effects of Gr-1+CD11b+
cells could also be due to their effect on angiogenesis, aswe pre-
viously reported (Yang et al., 2004).
Tumor-infiltrating Gr-1+CD11b+ myeloid cells are likely one of
the major sources for increased TGFb1 production observed in
mammary carcinomas with genetic deletion of Tgfbr2 (Figure 5).
This is demonstrated by the IHC of tumor sections showing that
TGFb1-positive cells are mostly stromal cells (Figure 5C), espe-
cially in the invasive front where Gr-1+CD11b+ cells were most
abundant. Our observation is supported by a recent publication
showing that, in response to Tgfbr2 deletion, there was in-
creased TGFb1 expression in the stroma (Lu et al., 2006). We
have now shown that Gr-1+CD11b+ cells are components of
these stromal cells. In addition, as Gr-1+CD11b+ cells produce
high levels of TGFb1, they are likely to have a major effect on
tumor evasion from host immune detection.
In summary, we have demonstrated that deletion of the type II
TGFb receptor gene in mammary carcinomas results in the re-
cruitment of Gr-1+CD11b+ myeloid cells through two distinct
mechanisms: SDF-1/CXCR4 as an intrinsic mechanism for
Gr-1+CD11b+ cells and CXCL5/CXCR2. Gr-1+CD11b+ cells
directly promote tumor metastasis through enhanced MMP
and TGFb production (Figure 8). Cellular and molecular targeting
of Gr-1+CD11b+ cell production/recruitment should not only
Figure 8. Mechanisms for Enhanced Tumor Progression Resulting
from Loss of TGFb Signaling
Deletion of the type II TGFb receptor gene in mammary carcinomas
results in elevated production of CXCL5, which interacts with CXCR2 on
Gr-1+CD11b+ cells, thus recruiting the cells into the tumor microenvironment.
Gr-1+CD11b+ cells, as hematopoietic cells, express high levels of CXCR4,
which interacts with SDF-1 in the tumor microenvironment, and are also re-
cruited. Gr-1+CD11b+ cells promote tumor invasion through high expression
of MMP14, MMP13, and MMP2. In addition, Gr-1+CD11b+ cells produce high
levels of TGFb1 that inhibit host immune surveillance.
Cancer Cell
TGFb Mediates Metastasis via Gr-1+CD11b+ Cellsimprove host immunosurveillance but also inhibit tumor metas-
tasis, having the effect of ‘‘killing two birds with one stone’’
and provide additional therapeutic options.
EXPERIMENTAL PROCEDURES
Cell Lines and Mice
The 4T1 breast cancer cell line was obtained from ATCC and maintained per
standard cell culture techniques. MMTV-PyVmT/Tgfbr2MGKO and floxed con-
trol cell lines were established as described (Forrester et al., 2005). Eight- to
ten-week-old female Balb/c mice were purchased from Harlan Inc. (Indianap-
olis, IN). Tgfbr2flox/flox, Tgfbr2MGKO, MMTV-PyVmT/Tgfbr2flox/flox, and MMTV-
PyVmT/Tgfbr2MGKO mice were established and maintained as described
(Forrester et al., 2005). The studies were approved by IACUC at Vanderbilt
University Medical Center.
Flow Cytometry Analysis
Single-cell suspensions were made from spleens and BM of normal and
tumor-bearing mice (Yang et al., 2004), and tumor tissues (Ljung et al.,
1989). These cells were labeled with fluorescence-conjugated antibodies
(BD PharMingen) and isotype-matched IgG controls. The cells were analyzed
on a FACScan flow cytometer (Becton Dickinson).
Single-Cell Sorting
Splenocytes from normal or tumor-bearing mice were stained with fluores-
cence-labeled antibodies and sorted with a FACStarPlus flow cytometer
(Becton Dickinson). Gr-1+CD11b+ cells were collected for tumor growth, inva-
sion, and migration experiments.
4T1 Breast Tumor Model for Metastasis
4T1 (53 105 cells), without or with Gr-1+CD11b+ cells (0.53 105), was injected
into the mammary fat pad of female Balb/c mice. Primary tumors were com-
pletely removed and weighed 12–14 days after tumor inoculation. The mice
were sacrificed 4 weeks later, and the lung metastasis was examined using
whole-lung mounting procedures. In addition, the weight of recurrent tumors
at the primary injection sites was also recorded.
Whole-Lung Mounting
Mice were sacrificed by anesthetic overdose. Lungs were processed as
described (Jessen et al., 2004). The tumor nodules in lung were then counted.
Immunohistochemistry and Immunofluorescence
Paraffin-embedded tumor sections were fixed in 4% paraformaldehyde and
incubated with a rat polyclonal anti-Gr-1 antibody (BD PharMingen), rabbit
polyclonal anti-myeloperioxidase (Abcam), or anti-TGFb1 (PharMingen). A
biotinylated second antibody was applied, followed by incubation with strep-
tavidin-conjugated HRP. Peroxidase activity was localized with diaminobenzi-
dine (Vectastain ABC kit, Vector Laboratories). For immunofluorescence,
anti-E-cadherin antibody (BD transduction laboratories, 1:500 dilution) was
applied to paraffin-embedded tumor sections; Alexa Fluor 488-conjugated
goat anti-mouse secondary antibody (Molecular Probes, 10 mg/ml) was used
to detect E-cadherin expression.
Immunoassay for Chemokines
Conditioned media and tissue lysates were analyzed for CXCL5 and TGFb1
expression by ELISA using commercial kits (R&D Systems).
In Vitro Cell Migration and Invasion Assays
For cell migration, Gr-1+CD11b+ cells (50,000) were seeded onto the top
chamber of transwell filters (8 mM, VWR Scientific). The filters were placed in
a 24-well plate that contains medium with recombinant mouse SDF-1 or
isotype control at 100 ng/ml. To neutralize CXCR4, the CXCR4 monoclonal
antibody at 10 mg/ml was added to the top chamber of the transwell. Migrated
Gr-1+CD11b+ cells were counted (five to seven fields per well, triplicate for
each experimental groups) 6–8 hr after incubation. For in vitro invasion assays,
4T1 cells were labeled with green fluorescence dye CMFDA (Molecular
Probes). Gr-1+CD11b+ cells were labeled with red fluorescence dye CMTMR.4T1 cells (30,000) alone or with Gr-1+CD11b+ cells (30,000) were seeded into
the top chamber of transwell filters coated with Matrigel (Becton Dickinson).
The filters were placed in a 24-well plate that contains culture media of 10%
FCS RPMI. Invaded 4T1 cells were counted (three fields per filter, triplicate
for each experimental groups) 6–8 hr after incubation.
In Vivo Inhibition of Gr-1+CD11b+ Cell Recruitment
to Breast Adenocarcinomas
MMTV-PyVmT/Tgfbr2MGKO and MMTV-PyVmT/Tgfbr2flox/flox tumors from do-
nor mice were cut into approximately 1 mm3 and planted into the #4 mammary
fat pad of syngeneic FVB recipient mice. Tumor size was determined 2 weeks
later as described (Yang et al., 2004). Mice with similar tumor size were treated
with the CXCR2-specific antagonist SB-265610 (GSK Pharmaceuticals) at
2 mg/kg/day through i.p. injection for 2 weeks (DMSO as vehicle). Tumor
size was measured again at the end of the treatment. For the effect of
CXCR2 and CXCR4 blockade on PyVmT/Tgfbr2MGKO tumor metastasis,
mice were implanted with tumors for 7 days and then were treated with
SB-265610 as described above, or a CXCR4 antagonist (AMD3100, Sigma,
at 1.25 mg/kg/day twice daily through s.c. injection, PBS as vehicle), or both
for 10 days. The primary tumors were then surgically removed. The mice
were allowed to live for another 3 weeks for lungmetastasis development with-
out further treatment. Metastasis nodules were counted. Primary tumors were
removed, weighed, and processed for HE staining.
In Situ Zymography of MMPs
Substrate (DQ-gelatin, Molecular Probes) was dissolved to a final concentra-
tion of 25 mg/ml in a mixture of 2% gelatin and 2% sucrose in PBS + 0.02%
sodium azide. One hundred microliters of this solution was then coated on
a slide, set on ice for 10 min, then stored at room temperature until next
day. Protease inhibitors including Aprotinin (2 mg/ml), Leupeptin (100 mM),
and pepstatin were included in the substrate solution to exclude other prote-
ase activities in addition to MMPs. EDTA (25 mM), an inhibitor of metallopro-
teinases, was used in negative controls. Frozen tumor sections (5–10 mm)
were cut directly onto the coated slides, and the slides were incubated in
dark at 30C for 24–36 hr. The slides were then mounted using an aqueous
fluorescence-saving mountant with 50 nM 7AAD, a nucleic acid stain (Mole-
cular Probes). The slides were then examined under a fluorescence micro-
scope.
Quantitative RT-PCR
Total RNA was extracted from sorted Gr-1+CD11b+ cells as described using
an RNeasy Mini Kit (QIAGEN Inc.). cDNA was synthesized using the Invitrogen
SuperScript first-strand synthesis system for RT-PCR. Primers specific for
MMP2, MMP13, and MT1-MMP were used, and relative gene expression
was determined using BioRad iCycler-iQ SYBR Green PCR kit (BioRad
Laboratories). The comparative threshold cycle method was used to calculate
gene expression normalized to b-actin as a gene reference. Primers were
designed using Beacon Designer 4 software and synthesized by Operon
(a QIAGEN company). Primer sequences are available upon request.
Human Breast Tumor Tissues
Human breast ductal adenocarcinomas (stages 2–3) were collected from
patients under surgery in Tianjing Cancer Institute, China, with written consent.
The sampleswere rinsed in cold PBS and put in RPMI supplementedwith FCS.
The samples were then processed to obtain single-cell suspension as de-
scribed earlier. The cells were then labeled with fluorescence-conjugated
antibodies (BD PharMingen) and isotype-matched IgG controls. The cells
were analyzed on a FACSaria flow cytometer (Becton Dickinson, Mountain).
Statistical Analysis
All data were analyzed by Student’s t test and were expressed as means ± SE,
and differences were considered statistically significant when p < 0.05.
Supplemental Data
The Supplemental Data include three supplemental figures and can be found
with this article online at http://www.cancercell.org/cgi/content/full/13/1/23/
DC1/.Cancer Cell 13, 23–35, January 2008 ª2008 Elsevier Inc. 33
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